Oral anticoagulants such as warfarin induce depletion of vitamin K-dependent coagulation factors, causing prolongation of the prothrombin time (PT) and the PT-International Normalized Ratio (INR). The available thromboplastins used for measuring the PT vary in their sensitivity to coagulation factor depletion, and each is assigned an International Sensitivity Index (ISI) that is used when calculating the INR. Traditional monitoring of oral anticoagulant therapy using the INR is confounded during concurrent therapy with direct thrombin inhibitors, such as argatroban, that also prolong the INR (1-3 ). Although alternative monitoring methods have been suggested for use in this setting (2, 3 ) , guidelines allowing for refined interpretation of the INR would also be useful. To facilitate the development of such guidelines, we have characterized in vitro the differential effects of warfarin and argatroban, as well as the choice of thromboplastin used, on the INR during anticoagulation with both agents.
For this study, plasma specimens were obtained from 10 healthy donors (laboratory personnel) and 35 patients on warfarin therapy, in accordance with policies of the Clinical Chemistry 45, No. 3, 1999 institution's responsible committee. Blood was collected into evacuated tubes (38 g/L sodium citrate), and plasma was prepared by the centrifugation of the blood within 30 min of collection. The only selection criterion for the patient group was that each was on warfarin therapy, and both inpatients and outpatients were included. In addition, four plasma pools (each prepared from at least 10 individuals) were obtained from Harris Laboratories. One plasma pool was from healthy donors, and three pools were from patients on warfarin therapy exhibiting generally similar levels of oral anticoagulation. Plasma specimens were stored at Ϫ30°C for up to 2 weeks and thawed rapidly immediately before testing. The PT of each individual or pooled plasma specimen was determined in the absence and presence of argatroban (NOVASTAN ® ; Texas Biotechnology Corp. and SmithKline Beecham Pharmaceuticals) added in vitro at three different, clinically-relevant concentrations (0.5, 1.0, and 2.0 mol/L, final concentration). The argatroban concentrations were selected to emulate those typically attained with infusion doses of 1, 2.5, and 5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 , respectively (4, 5 ) . The PT assays on the individual plasma specimens were performed using Thromborel S (ISI ϭ 1.11; Behring) on a Fibrintimer A (Behring). The PT assays on the pools were performed using Thromborel S (different lot, ISI ϭ 1.05), Thromboplastin C-Plus (ISI ϭ 1.92, Dade), and Simplastin Excel (ISI ϭ 2.01, Organon Teknika) on a Coag-A-Mate XC (Organon Teknika). For each PT determined, the INR was calculated (6 ) using the thromboplastin-specific ISI and the following equation:
INR ϭ ͑PT specimen/mean normal PT͒ ISI
We performed analysis of variance on INR values from the plasma pools, using a general linear model. For all paired specimens, INR values in the presence of argatroban ("combined INR") were regressed on INR values in the absence of argatroban ("warfarin INR"). Data were logarithmically transformed to adjust for heteroscedasticity. Six regressions were evaluated, one for each combination of argatroban concentration (0.5, 1.0, and 2.0 mol/L) and thromboplastin sensitivity (ISI of ϳ1 or ϳ2). For each combination, the data were fitted using a cubic polynomial model, and sequential tests of the regression coefficients indicated that only the linear effect was significant (i.e., the quadratic and cubic effects were nonsignificant). Tests for common intercept and common slope were performed to evaluate the comparability of the two reagent lots used, with an ISI of ϳ1, and of the two different reagents used, with ISI values of ϳ2. We used the log-transformed data to estimate 95% prediction intervals for the combined INR at each warfarin INR for each of the six combinations of argatroban concentration and thromboplastin sensitivity. The error in the warfarin INR predicted from a combined INR was estimated as the half-width of the inverse prediction interval. Fig. 1 shows the arithmetic linear relationships between the paired INR values measured in the absence or presence of argatroban, using the thromboplastin with an ISI of ϳ1 ( Fig. 1A ) and the two thromboplastins with ISI values of ϳ2 ( Fig. 1B ). Tests of common intercept and common slope indicated that the two different lots of the low ISI thromboplastin (ISI values of 1.05 and 1.11) were comparable, as were the two different thromboplastins with ISI values of 1.92 and 2.01. Irrespective of the choice of thromboplastin, the combined INR increased linearly with the warfarin INR at each plasma argatroban concentration tested (r Ն0.95). The sensitivity of the combined INR to the warfarin INR (i.e., the slope of the regression line) increased significantly (P Ͻ0.0001) with plasma argatroban concentration over the range evaluated. In addition, the sensitivity of the combined INR to argatroban increased when the ISI of the thromboplastin increased approximately twofold (ISI values of ϳ1 vs ϳ2; P Ͻ0.0001).
The variance about the regression lines increased with INR, but was homogeneous when the data were logarithmically transformed. On the basis of the inverse 95% prediction intervals of the log-transformed data, the error in the warfarin INR predicted from a combined INR tended to increase with plasma argatroban concentration for the thromboplastin with ISI of ϳ1, but not the for the thromboplastin with ISI ϳ2. The maximum errors (detransformed to the arithmetic scale) in the predicted warfarin INR for a combined INR of 5 were Ϯ 0.4, Ϯ0.5, and Ϯ 0.6 INR units, respectively, for 0.5, 1.0, and 2.0 mol/L argatroban, respectively. At the same respective argatroban concentrations, the maximum prediction errors for a combined INR of 7 were Ϯ 0.5, Ϯ0.7, and Ϯ 0.9 INR units, respectively.
We concluded that the combined effects exerted by warfarin and argatroban anticoagulation on the INR are sensitive to the degree of warfarin-induced factor depletion, the plasma argatroban concentration, and the thromboplastin used. Specifically, the use of a low-ISI thromboplastin minimized the combined effects. In addition, these combined effects can be modeled linearly ( Fig. 1) . It may be possible to exploit this model to predict the contribution of warfarin to the INR during concurrent argatroban therapy, given knowledge of the combined INR, the plasma argatroban concentration, and the thromboplastin used. Although the relationship between the differential contribution of warfarin to the combined INR and bleeding risk during concurrent argatroban therapy remains to be established, a predicted warfarin INR could be useful for approximating the degree of anticoagulation expected upon cessation of argatroban or perhaps for adjusting warfarin dosage during argatroban therapy. However, on the basis of the estimated error in the predicted warfarin INR, this model may have limited clinical utility for specimens containing Ͼ1.0 mol/L argatroban (or hence for argatroban infusion doses greater than ϳ2.5 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ). For combined INR values of 5 and 7, for example, the maximum error in the predicted INR was generally acceptable (i.e., less than or equal to Ϯ 0.5 units) at 0.5 mol/L argatroban, yet it became less acceptable (i.e., up to Ϯ 0.9 units) at 2.0 mol/L argatroban. The development of a similar model based on argatroban dosage rather than concentration may be feasible because these parameters are linearly related (4 ) and would perhaps further facilitate practical application of the model.
The differential effects of warfarin and argatroban on the INR (Fig. 1) were evaluated using the INR values of healthy donors and patients (both inpatients and outpatients), as well as pools of these individuals, determined in the presence and absence of argatroban. The variability in the model therefore would be expected to reflect, at least in part, interindividual variability in factors other than warfarin and argatroban that could possibly influence the INR, such fibrinogen and fibrin degradation products. Another factor, if present, that could potentially influence the INR would be an argatroban metabolite. However, argatroban has only one metabolite that can be detected in plasma, and it exerts no significant anticoagulant effects at clinically relevant concentrations (7 ).
In clinical laboratories, many different combinations of thromboplastin and clot detection instruments are used for determining the INR (8 ). In this study, four different combinations of thromboplastins and instruments were used for determining INR values, and for each combination, the combined effects exerted by argatroban and warfarin on the INR could be modeled linearly. The thromboplastins used were of plain composition (i.e., not combined with adsorbed plasma nor of recombinant source), with ISI values of ϳ1 and ϳ 2. One could speculate that for a given argatroban concentration, the sensitivity of the combined INR to the warfarin INR for a thromboplastin with an intermediate ISI value (e.g., 1.3 or 1.8) would fall between those for thromboplastins with ISI values of 1 and 2. Future confirmatory studies that evaluate other combinations of instruments and thromboplastins, including perhaps those of different ISI values and of different type (combined or recombinant), may be valuable.
The extent to which these conclusions apply to other oral anticoagulants and antithrombin agents is not yet clear. However, on the basis of these promising in vitro results, clinical studies have been initiated to define this model more fully and to investigate further the utility of the INR, with refined interpretation, for monitoring warfarin during concurrent argatroban therapy. 
Plasma Homocysteine Determined by Capillary Electrophoresis with Laser-induced Fluorescence Detection,
Elizabeth Caussé, 1* Nathalie Siri, 1 Hélène Bellet, 2 Sandrine Champagne, 1 Christophe Bayle, 3 Pierre Valdiguié, 1 Robert Salvayre, 1 Homocysteine (Hcy) has emerged as another risk factor for the development of coronary heart disease (1 ) . Genetic abnormalities of the enzymes cystathionine-␤-synthase and methylene tetrahydrofolate reductase (folic acid and vitamin B 6 and B 12 cofactors) can cause raised plasma Hcy concentrations. Deficiencies in folic acid and vitamins B 6 and B 12 may also contribute to this increased concentration (1) (2) (3) . Consequently, patients with coronary heart disease have been treated successfully with folic acid, vitamin B 12 , or vitamin B 6 (1 ), but the benefit of such treatment in reducing morbid cardiovascular endpoints is presently unknown (3 ) . A widely used technique for measuring total plasma Hcy is reversed-phase HPLC with fluorescence detection after derivatization of plasma thiols (4 -6 ) . Some studies use gas chromatography-mass spectrometry techniques (7 ) with various derivatization protocols (8 ).
The increasing demand for the determination of plasma total Hcy prompted us to develop a rapid, automated method based on capillary electrophoresis (CE) and laserinduced fluorescence detection (LIF) , in which all specific thiols are detected selectively.
Blood was collected by venipuncture into evacuated tubes containing EDTA from patients with episodes of deep-vein thrombosis or vascular disease. The plasma was separated by centrifugation and was stored at Ϫ20°C until analysis.
Plasma samples (100 L) were treated for 30 min at room temperature with 10 L of a novel thiol-reducing agent [35 mmol/L tris(2-carboxyethyl)phosphine; Molecular Probes], as reported recently by Gilfix et al. (9 ) . Compared with the widely employed tributyl phosphine, this new phosphine is nonvolatile, stable, soluble in water, and without disagreeable odor (5, 6 ) . When we used this procedure, total Hcy (mixed and symmetric disulfides, including protein-bound Hcy) was analyzed in its reduced form.
All patient samples and plasma-based calibrators were incubated with tris(2-carboxyethyl)phosphine under the same conditions. The internal standard [5 L of 10 mmol/L d-penicillamine (DP)] was mixed with plasma. The solution was deproteinized with 60 L of 0.8 mol/L 5-sulfosalicylic acid with vortex-mixing, followed by centrifugation at 10 000g for 15 min.
We mixed 100 L of the supernatant with 50 L of 0.3 mol/L carbonate buffer, pH 9.5, and 5 L of 5 mol/L sodium hydroxide. We then added 50 L of a 1 g/L 6-iodoacetamidofluorescein solution (6-IAF) in dimethyl sulfoxide (Sigma Chemical Co.), and the mixture was incubated overnight in the dark at room temperature to allow analysis after the reaction has plateaued (Ͼ2 h). IAF-labeled samples were stored at Ϫ20°C until analysis; they could be preserved for up to 3 months. Each derivatized plasma was analyzed directly after being diluted 5000-fold before the CE injection. The analyses were performed on a Zeta CE instrument (Zeta Technology) equipped with a modular LIF detector and an argon ion laser (wavelength, 488 nm). The different thiols were separated on a 75 cm ϫ 50 m (i.d.) fused-silica capillary (Polymicro Technology) with an effective length of 43 cm and a total length of 75 cm. The separation buffer consisted of 10 mmol/L sodium dodecyl sulfate, 50 mmol/L boric acid, and 20 mmol/L 3-(cyclohexylamino)-1-propanesulfonic acid adjusted to pH 9.5 by addition of a sodium hydroxide solution (10 mol/L). The separation voltage was ϩ25 kV, producing an electrophoretic current of 25 A.
All samples were assayed in triplicate. Peaks were identified by use of solutions of Hcy, Cys, or glutathione, and the internal standards cysteamine or DP. Fig. 1A shows the thiol solutions prepared in carbonate 0.3 mmol/L buffer, pH 9.5, and then diluted in deionized water. Under the electrophoretic conditions used, the Hcy derivative is well separated with a migration time of 7.2 min.
Electropherograms of a human plasma sample with added DP as internal standard produced several peaks (Fig. 1, B and C) . Known quantities of Hcy, Cys, or DP solutions were added to the plasma sample to identify Hcy, Cys, and DP peaks.
Hcy calibrators were prepared from a plasma pool (30, 15, 10, 5, and 2 mol/L), and the concentrations were calculated according to peak heights. The calibration curves for Hcy quantification were obtained by plotting the peak height ratio of Hcy/DP and Hcy/Cys. The equations, as a function of the Hcy concentration x (expressed in mol/L) were, respectively, as follows: y ϭ 0.033x ϩ 0.013 (r ϭ 0.9998) for Hcy/DP and y ϭ 0.011x ϩ 0.003 (r ϭ 0.9992) for Hcy/Cys.
The detection response was linear over the concentration range between 2 and 200 mol/L for all the plasma
